#1
#1 out of 10.00%
business2h ago
Key facts: Ionis licenses salanersen to Biogen; sees >$7B peak
- Ionis licenses salanersen to Biogen, aiming for a potential high-revenue SMA successor.
- Biogen earned FDA Breakthrough designation and advances three Phase 3 studies.
- Ionis projects over $7 billion peak annual revenue by 2028 due to late-stage programs.
- The deal aligns Ionis with Biogen on a neurology-focused portfolio.
- Salanersen is viewed as a potential SMA treatment successor in Ionis' portfolio.
- Ionis emphasizes cash flow growth alongside its RNA platform expansion.
- The announcement underscores ongoing collaboration between Ionis and Biogen.
- TradingView reports the news and context for Ionis and Biogen's collaboration.
- The deal could impact Ionis' revenue trajectory through 2028 and beyond.
- The partnership emphasizes potential long-term value from an RNA-based platform.
Vote 0